Article Text

PDF
OC-067 A single-blinded study evaluating the effects of a gluten-free diet in diarrhoea-predominant irritable bowel syndrome
  1. I Aziz,
  2. J North,
  3. N Trott,
  4. R Briggs,
  5. DS Sanders
  1. Academic Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK

Abstract

Introduction Gluten has been shown to alter bowel barrier function in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS), particularly those who are HLA-DQ positive.

Aims To assess the clinical response to a gluten-free diet (GFD) in D-IBS patients previously naïve to the effects of gluten and blinded to HLA-DQ status.

Method Between May 2012 to December 2014 we enrolled 48 D-IBS patients (24 HLA-DQ positive and 24 HLA-DQ negative) to undertake a six-week GFD. Patients commenced a GFD after seeing an expert dietitian. Both patients and dietitian were blinded to HLA-DQ status. Questionnaires were self-completed at baseline and at week 6. The primary end-point was change in IBS-symptom severity score (IBS-SSS), with a 50 point reduction conferring clinical benefit. Secondary end-points were change in IBS-quality of life (IBS-QOL), short form-36 (SF-36), hospital anxiety and depression score (HADS) and fatigue impact score (FIS).

Results Data from 41 patients (74.4% women, mean-age 40.3 yrs) was available for per protocol analysis. Of these, 21 were HLA-DQ positive and 20 HLA-DQ negative; baseline characteristics were similar other than worse physical-fatigue (0.04) and vitality (0.05) in the HLA-DQ positive group. Overall, a GFD reduced IBS-SSS ≥50 points in 76% (n = 31). In fact, the mean-total IBS-SSS decreased from 286 to 131 (change –155, p < 0.001); this was seen similarly across both HLA-DQ groups. There was also a significant improvement in IBS-QOL, SF-36, HADS, and FIS amongst both groups. However, HLA-DQ positive subjects showed a greater response to depression (p = 0.02), fatigue (physical, p = 0.04; cognitive, p = 0.07) and vitality (p = 0.05) compared to HLA-DQ negative subjects. On study completion, 90% (n = 37) were discharged and 61% (n = 25) continued with a GFD.

Conclusion A GFD is a therapeutic option for the management of D-IBS. A clinical improvement was seen in 76% of patients undertaking a six-week GFD, with 61% opting to continue with a GFD for the foreseeable future. The pathophysiological mechanism may differ according to HLA-DQ status.

Disclosure of interest None Declared.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.